British firm GSK to move malaria vaccine production to Bharat Biotech

Topics Bharat Biotech | GSK

GSK will continue to supply Bharat Biotech with the adjuvant or vaccine booster for the shot
British firm GSK, Bharat Biotech and PATH, a non-profit organisation, have signed a product transfer agreement for the malaria vaccine RTS,S/AS01.

The agreement includes transfer of manufacturing of the protein part of the malaria vaccine, while GSK will continue to supply Bharat Biotech with the adjuvant or vaccine booster for the shot, a joint statement said.

Krishna M Ella, Chairman & Managing Director, Bharat Biotech, said: “We are honoured to support this partnership and to provide global access to RTS,S/AS01E. Bharat Biotech is geared up for large-scale manufacturing, and to provide continuous long-term supply of this life-saving vaccine.” 

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel